# Diabeloop

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/diabeloop-s-a

- Industry: Medical Devices & Equipment
- Headquarters: Grenoble, France
- Website: www.diabeloop.com
- Latest round: Series C (Jun 2, 2022)
- Investors on record: 11

## About

Diabeloop S.A. specializes in developing innovative medical devices that automate and personalize diabetes management, particularly for individuals with Type 1 diabetes, through advanced artificial intelligence technology.Diabeloop S.A. was founded in 2015 and is headquartered in Grenoble, France. The company focuses on automating diabetes treatment with its flagship product, the DBLG1. Erik Huneker, the founder, has a background in healthcare technology. The latest funding round, which took place in June 2022, involved raising EUR 21.233 mn, led by Cemag Invest, among other investors, contributing to a total amount raised of EUR 21.233 mn. The company's current valuation is EUR 53.740 mn.Diabeloop specializes in the development of advanced medical devices designed to automate and personalize the treatment of Type 1 diabetes. Its core product, the DBLG1, utilizes a self-learning algorithm that integrates therapeutic artificial intelligence to significantly alleviate the daily management burden faced by individuals with diabetes. This hybrid closed-loop system operates by connecting to a continuous glucose monitor (CGM) and an insulin pump, allowing for real-time analysis of glucose levels and the adjustment of insulin delivery based on the patient’s physiological data and lifestyle factors. Diabeloop primarily targets adults with Type 1 diabetes and markets its offerings in France and several other European countries, forming partnerships with international organizations like Roche Diabetes Care and Terumo Corporation for expansion purposes.In 2022, Diabeloop generated a revenue of EUR 3,808,997.20, while reporting an EBITDA of EUR -16,466,246.40 for the same year. The revenue model is based on the direct sale of its medical devices, requiring prescriptions, and transactions facilitated through partnerships with international distributors and medical facilities, ensuring compliance and safety with CE marks for its devices.In June 2022, Diabeloop S.A. raised EUR 21.233 mn in venture debt funding from Bpifrance, part of a larger EUR 70 million Series C funding round. The company intends to utilize this funding to boost its global expansion efforts, including the launch of new products and entry into additional markets. Specific geographic markets targeted for expansion and timelines for product launches are currently under development.

## Funding rounds

- Series C, Jun 2, 2022 — Innovacom, Kreaxi, LBO France, Groupe Crédit Agricole, Odyssee Venture, Terumo Corporation, Cemag Invest, Supernova Invest, AGIR à dom, CERITD, UI Investissement

## Investors

- Innovacom (https://capitalatlas.ai/funds/innovacom) — Series C
- Kreaxi (https://capitalatlas.ai/funds/kreaxi) — Series C
- LBO France (https://capitalatlas.ai/funds/lbo-france) — Series C
- Groupe Crédit Agricole — Series C
- Odyssee Venture (https://capitalatlas.ai/funds/odyssee-venture) — Series C
- Terumo Corporation — Series C
- Cemag Invest — Series C
- Supernova Invest (https://capitalatlas.ai/funds/supernova-invest) — Series C
- AGIR à dom — Series C
- CERITD — Series C
- UI Investissement (https://capitalatlas.ai/funds/ui-investissement) — Series C